ALK and non-small cell lung carcinoma: In this phase III study, 358 patients with stage IB-IIIA (AJCC v 8) resectable NSCLC and without EGFR/ALK alterations were randomly assigned to neoadjuvant nivolumab 360 mg every three weeks for three cycles (358 participants) along with platinum-based doublet chemotherapy vs. chemotherapy alone [4].